PDCD1 and chronic hepatitis B virus infection: On one hand, previous clinical studies had shown that PD-1 inhibitors led to HBsAg decline and contributed to the acquisition of clinical cure in patients with chronic hepatitis B (Gane et al. 2019; Fisicaro et al. 2010).